SCHEMBL4746017

SCHEMBL4746017

c1cnc2c(c1)-c1cccc3c1c-2cc1c2ccccc2c(-c2ccc4ncccc4c2)cc31

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
DYRK1A Q13627 1/20 0.42
TGFBR1 P36897 2/20 0.40
GRM4 Q14833 1/20 0.40
ADORA2A P29274 2/20 0.39
PSMD14 O00487 1/20 0.39
TP53 P04637 1/20 0.39
MMP2 P08253 1/20 0.39
CYP1B1 Q16678 1/20 0.39
ADORA1 P30542 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13320888 0.91 POLB (0.53) POLBNPC1RAB9ADYRK1AGRM4
SCHEMBL4746020 0.90 TGFBR1 (0.40) POLBNPC1RAB9ATGFBR1ALDH1A1
SCHEMBL4745816 0.90 HTR2B (0.40) NPC1RAB9AADORA2AADORA1ALDH1A1
SCHEMBL4746386 0.90 ALDH1A1 (0.38) TGFBR1ADORA2AADORA1ALDH1A1HPGD
SCHEMBL4746015 0.89 PDGFRB (0.45) POLBNPC1RAB9ADYRK1ATYK2
SCHEMBL4746384 0.88 ALDH1A1 (0.37) TGFBR1ADORA2AADORA1ALDH1A1HPGD
SCHEMBL4746287 0.87 PTPRC (0.39) TGFBR1ALDH1A1HPGDTSHRMAPK1
SCHEMBL4746252 0.86 ALDH1A1 (0.41) POLBNPC1RAB9ATP53ALDH1A1
SCHEMBL4746300 0.85 PTPRC (0.38) TGFBR1ALDH1A1HPGDTSHRMAPK1
SCHEMBL4746298 0.85 PTPRC (0.38) TGFBR1ALDH1A1HPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 POLB 2469/4885NPC1 3564/4885RAB9A 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.